Item 7.01 Regulation FD Disclosure.

On November 4, 2009, Transcept Pharmaceuticals, Inc. ("Transcept") issued a press release announcing its receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for claims under U.S. patent application no. 11/833,323, which covers the use of Intermezzo®(zolpidem tartrate sublingual tablet), the lead Transcept product candidate.

The full text of the press release is furnished herewith as Exhibit 99.1. The furnishing of the attached information is not an admission as to the materiality of any of the information set forth therein.

The information in this Item 7.01 and in Item 9.01 of this Current Report on Form 8-K and the Exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section, or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit
No. Description

99.1 Press Release Regarding Notice of Allowance, dated November 4, 2009

---